NeuroSense Therapeutics Granted South Korean Patent for Lead ALS Candidate PrimeC

On June 11, 2026, NeuroSense Therapeutics Ltd. announced that the Korean Intellectual Property Office (KIPO) has granted Korean Patent Number 10-2969898. This patent covers the composition of PrimeC, the company’s lead oral drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). The granted claims encompass PrimeC’s proprietary tablet formulation, manufacturing process, pharmacokinetic characteristics, and pharmaceutical use in ALS. The patent is expected to provide protection in South Korea through 2042. This regulatory milestone follows similar patent grants in the United States, Japan, Brazil, and Australia, strengthening the company's global intellectual property portfolio. PrimeC is a fixed-dose combination of ciprofloxacin and celecoxib designed to target neuroinflammation and oxidative stress. NeuroSense has previously reported positive Phase 2b PARADIGM study results and has received FDA clearance to initiate the pivotal Phase 3 PARAGON study, which will enroll approximately 300 participants. The company is also investigating PrimeC for the treatment of Alzheimer's disease.